This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Nextech Trims Kymera at a Recent High — think Foolishly before acting. Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise spending and payments.
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
